(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 May 2012 (03.05.2012)

PCT

(10) International Publication Number
WO 2012/058392 A1

(51) **International Patent Classification**:
A61K 9/14 (2006.01) ***A61K 47/12*** (2006.01)
A61K 31/437 (2006.01) ***A61K 47/34*** (2006.01)
A61K 47/22 (2006.01) ***A61K 47/38*** (2006.01)
A61K 47/26 (2006.01) ***A61K 47/44*** (2006.01)
A61K 47/32 (2006.01) ***A61P 35/00*** (2006.01)
A61K 9/48 (2006.01)

(21) **International Application Number**:
PCT/US2011/058024

(22) **International Filing Date**:
27 October 2011 (27.10.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/408,517 29 October 2010 (29.10.2010) US

(71) **Applicant** *(for all designated States except US)*: **ABBOTT LABORATORIES** [US/US]; 100 Abbott Park Road, Abbott Park, Illinois 60064 (US).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **CATRON, Nathaniel D.** [US/US]; 305 Lakeside Drive, Vernon Hills, Illinois 60061 (US). **LINDLEY, David J.** [US/US]; 676 Needlegrass Parkway, Antioch, Illinois 60002 (US). **MILLER, Jonathan** [US/US]; 1228 Meade Drive, Lindenhurst, Illinois 60046 (US). **SCHMITT, Eric A.** [US/US]; 319 Evergreen Court, Libertyville, Illinois 60048 (US). **TONG, Ping** [CN/US]; 1520 Eric Lane, Libertyville, Illinois 60048 (US).

(74) **Agents**: **MANZARI, Oona A.** et al.; 100 Abbott Park Road, AP6A-1/D0377, Abbott Park, Illinois 60064 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2012/058392 A1

(54) **Title**: SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT

(57) **Abstract**: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.